Metabolic syndrome associated with increased risk of endometrial cancer
the ONA take:
Past research has indicated that metabolic syndrome increased older women’s the risk of endometrial cancer, the most common cancer of the female reproductive organs. However, whether the association was due to obesity or metabolic syndrome was unclear.
A new study from the National Institutes of Health demonstrated that metabolic syndrome is associated with increased risk of endometrial cancer. Metabolic syndrome is a cluster of factors that increase a person’s risk of cardiovascular disease, stroke, diabetes, and other metabolic-related diseases.
Using the SEER-Medicare Linked Database, the researchers reviewed information from 16,323 women ages 65 years and older with endometrial cancer diagnosed between 1993 and 2007, along with 100,751 women who did not have the disease.
A diagnosis of metabolic syndrome was determined using criteria set by either the US National Cholesterol Education Program Adult Treatment Panel III (ATP III) or the International Diabetes Foundation.
The researchers found women with metabolic syndrome as determined by the ATP III criteria were 39% more likely to develop endometrial cancer, and those with metabolic syndrome as determined by International Diabetes Foundation criteria were 109% more likely to develop endometrial cancer. After accounting for overweight or obesity among the women, the risk of developing endometrial cancer were 21% higher and 17% higher, respectively.
In addition, excessive weight, hypertension, high triglycerides, and impaired fasting glucose—all factors in metabolic syndrome—increased women’s risk of developing endometrial cancer individually.
Whether the association with endometrial cancer was due to obesity or metabolic syndrome was unclear.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|